MedWatch

Rhovac is open to all sale and partnership opportunities

The biotech company Rhovac has yet again initiated plans for a potential transaction – or a partnership. According to CEO Anders Månsson, the company is "ready for everything."

Photo: Gregers Tycho/IND

All paths are open when it comes to the biotech company Rhovac's journey foward. That is, as long as the results of the ongoing phase IIb trial with its lead candidate, RV001, which is a RhoC-based cancer vaccine, look promising, CEO at Rhovac Anders Månsson tells MedWatch.

On Monday, the Danish biotech business, which is listed in Sweden, announced that it had retained the international investment bank Stifel Nicolaus Europe, and together had begun looking into transaction or partnership opportunities for RV001.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs